In a study that included nine patients with advanced NKTCL, PD-1 inhibitors in combination with P-GemOx chemotherapy showed an ORR of 88.9% and a CR rate of 77.8%, a 1-year PFS rate of 66.7%, and a 1-year OS rate of 100.0% (105). The gene discussed is RPL17; the disease is extranodal nasal NK/T cell lymphoma.